Philip L. Johnson
Known title: EVP & Chief Financial OfficerCIK: 0002013156
Philip L. Johnson's purchase track record
Philip L. Johnson has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/1/2024 | JAZZ | $1.44M | -11.4% | -2.4% | +10.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| JAZZ | ▼ Sell | Tax Withholding | 3,343 | $795K | 6/30/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 2,615 | $493K | 3/5/2026 | View on chart |
| JAZZ | ▲ Buy | Grant | 11,857 | $0 | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Other | 1,149 | $160K | 3/5/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 7,704 | $0 | 2/27/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 15,407 | $0 | 2/27/2025 | View on chart |
| JAZZ | ▲ Buy | Open Market | 12,000 | $1.4M | 3/1/2024 | View on chart |
| JAZZ | ▲ Buy | Grant | 15,932 | $0 | 3/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JAZZ: Ziihera FDA win and leadership change shift company outlook
Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.
JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.